{
    "clinical_study": {
        "@rank": "16697", 
        "arm_group": [
            {
                "arm_group_label": "LBR-101 IV Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "LBR-101 Dose 1 Administered Intravenously"
            }, 
            {
                "arm_group_label": "LBR-101 SC Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "LBR-101 Dose 1 Administered Subcutaneously"
            }, 
            {
                "arm_group_label": "Placebo IV", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Administered Intravenously"
            }, 
            {
                "arm_group_label": "Placebo SC", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Administered Subcutaneously"
            }, 
            {
                "arm_group_label": "LBR-101 Dose 2 IV", 
                "arm_group_type": "Experimental", 
                "description": "LBR-101 Dose 2 Administered Intravenously"
            }, 
            {
                "arm_group_label": "LBR-101 Dose 2 SC", 
                "arm_group_type": "Experimental", 
                "description": "LBR-101 Dose 2 Administered Subcutaneously"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, tolerability and blood levels of LBR-101\n      when administered intravenously or subcutaneously to healthy volunteers."
        }, 
        "brief_title": "Safety and Bioavailability of IV and SC LBR-101", 
        "condition": "Bioavailability and Pharmacokinetics", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Generally Healthy, Signed Approved Informed Consent, BMI 17.5-34.5 kg/m2, Willing and\n             able to comply with CRU rules regulations and study schedule\n\n        Exclusion Criteria:\n\n          -  Clinically significant medical or psychiatric condition, Febrile illness within 5\n             days of dosing, Pregnant or Nursing Females. History of alcoholism, drug addiction or\n             positive drug/alcohol screen, History of hypersensitivity to injected proteins or\n             monoclonal antibodies, Unwilling or unable to comply with the protocol specified\n             lifestyle guidelines, Investigational site staff members, Use of 3 or more\n             prescription or non-prescription medications daily, Acetaminophen use in doses of\n             higher than 1 g or more/day, Daily Aspirin use in higher than 325 mg/day,  Treatment\n             with an investigational drug within 30 days of dosing, Use of biologics within 6\n             months of screening, Any clinically significant abnormality in the 12-Lead ECG,\n             Positive result for HIV, Hepatitis B, or Hepatitis C, Any clinically significant\n             abnormalities in Blood Chemistry Hematology or Urinalysis, Positive Pregnancy Test."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991509", 
            "org_study_id": "LBR-101-011"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LBR-101 IV Dose 1", 
                    "Placebo IV", 
                    "LBR-101 Dose 2 IV"
                ], 
                "description": "LBR-101 Administered Intravenously", 
                "intervention_name": "LBR-101 IV", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "LBR-101 SC Dose 1", 
                    "Placebo SC", 
                    "LBR-101 Dose 2 SC"
                ], 
                "description": "LBR-101 Administered Subcutaneously", 
                "intervention_name": "LBR-101 SC", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78744"
                }, 
                "name": "PPD Development"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study Assessing the Safety, Tolerability and Pharmacokinetics of Two Different Doses of LBR-101 Given Intravenously and Subcutaneously", 
        "overall_official": [
            {
                "affiliation": "Sponsor Chief Medical Officer", 
                "last_name": "Marcelo Bigal, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Sponsor Clinical VP", 
                "last_name": "Rafael Escandon, PhD MPH", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Relative bioavailability of IV versus SC Administration of LBR-101", 
            "safety_issue": "No", 
            "time_frame": "30 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991509"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Labrys Biologics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Labrys Biologics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}